TC BioPharm raised €1.7M (£1.18) to treat UK-based patients with melanoma, lung and kidney cancer. Thanks to this funding, the Phase I/II clinical studies will start as of September in several parts of the country.
TC BioPharm’s lead product, ImmuniCell, uses patients’ own cells grown in culture to target a wide variety of different cancers. The product has a safe and efficacious history of use based on the treatment of numerous patients by TC BioPharm’s strategic pharma-partner, Japanese Medinet. In addition to treating cancer, ImmuniCell’s platform has the potential to target major viral infections such as severe influenza, HIV and Ebola.
Since the beginning of the operations, 16 months ago, the company has raised over £3.3 million in seed equity and grants. These funds, and the support from those who contributed, have allowed the British biopharma to accomplish its goal: start treating cancer patients.